Last reviewed · How we verify
Mictonetten 5 mg, coated tablet
Mictonetten is a muscarinic M3 receptor antagonist that reduces bladder muscle contractions to treat overactive bladder symptoms.
Mictonetten is a muscarinic M3 receptor antagonist that reduces bladder muscle contractions to treat overactive bladder symptoms. Used for Overactive bladder with symptoms of urinary urgency, frequency, and incontinence.
At a glance
| Generic name | Mictonetten 5 mg, coated tablet |
|---|---|
| Also known as | Mictonetten |
| Sponsor | APOGEPHA Arzneimittel GmbH |
| Drug class | Antimuscarinic agent |
| Target | M3 muscarinic receptor |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | Phase 3 |
Mechanism of action
The drug blocks M3 muscarinic receptors on the detrusor muscle of the bladder, decreasing involuntary contractions and increasing bladder capacity. This mechanism reduces urinary frequency, urgency, and incontinence episodes characteristic of overactive bladder disorder.
Approved indications
- Overactive bladder with symptoms of urinary urgency, frequency, and incontinence
Common side effects
- Dry mouth
- Constipation
- Blurred vision
- Urinary retention
- Headache
Key clinical trials
- Dose-Escalating Study of Propiverine Hydrochloride in Children Suffering From Overactive Bladder (PHASE2)
- Propiverine in Children Suffering From Non-Neurogenic Overactive Bladder and Urinary Incontinence (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mictonetten 5 mg, coated tablet CI brief — competitive landscape report
- Mictonetten 5 mg, coated tablet updates RSS · CI watch RSS
- APOGEPHA Arzneimittel GmbH portfolio CI